CNS Pharmaceuticals Inc.

0.2648-0.0131-4.71%Vol 1.28M1Y Perf -86.51%
Jun 24th, 2022 16:00 DELAYED
BID0.2648 ASK0.2778
Open0.2649 Previous Close0.2779
Pre-Market- After-Market0.26
 - -  0.00 -1.66%
Target Price
6.00 
Analyst Rating
Strong Buy 1.00
Potential %
2.17K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.80 
Earnings Rating
Market Cap10.60M 
Earnings Date
12th Aug 2022
Alpha-0.08 Standard Deviation0.20
Beta1.82 

Today's Price Range

0.25700.2875

52W Range

0.24532.68

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-5.43%
1 Month
-11.08%
3 Months
-20.93%
6 Months
-69.56%
1 Year
-86.51%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CNSP0.2648-0.0131-4.71
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.07-
Q04 2021-0.21-0.1052.38
Q03 2021-0.21-0.1433.33
Q02 2021-0.16-0.156.25
Q01 2021--0.15-
Q04 2020-0.09-0.18-100.00
Q02 2020--0.15-
Q01 2020--0.12-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.28M
Shares Outstanding40.03K
Shares Float31.18M
Trades Count1.93K
Dollar Volume340.41K
Avg. Volume1.58M
Avg. Weekly Volume2.97M
Avg. Monthly Volume911.91K
Avg. Quarterly Volume863.07K

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) stock closed at 0.2648 per share at the end of the most recent trading day (a -4.71% change compared to the prior day closing price) with a volume of 1.28M shares and market capitalization of 10.60M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3 people. CNS Pharmaceuticals Inc. CEO is John M Climaco.

The one-year performance of CNS Pharmaceuticals Inc. stock is -86.51%, while year-to-date (YTD) performance is -62.3%. CNSP stock has a five-year performance of %. Its 52-week range is between 0.2453 and 2.68, which gives CNSP stock a 52-week price range ratio of 0.80%

CNS Pharmaceuticals Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.76, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -91.03%, a ROC of -99.14% and a ROE of -101.42%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from CNS Pharmaceuticals Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. CNS Pharmaceuticals Inc.’s next earnings report date is 12th Aug 2022.

The consensus rating of Wall Street analysts for CNS Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6, which is +2 165.86% compared to the current price. The earnings rating for CNS Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CNS Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CNS Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.14, ATR14 : 0.03, CCI20 : -97.21, Chaikin Money Flow : -0.52, MACD : -0.01, Money Flow Index : 80.12, ROC : -14.58, RSI : 39.07, STOCH (14,3) : 6.51, STOCH RSI : 0.00, UO : 29.87, Williams %R : -93.49), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CNS Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma.

CEO: John M Climaco

Telephone: +1 800 946-9185

Address: 2100 West Loop South, Houston 77027, TX, US

Number of employees: 3

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

58%42%

Bearish Bullish

54%46%

News

Stocktwits